ESMO Asia 2023 is on the horizon, and prominent pharmaceutical companies like Seagen, Hutchmed, and others are poised for the conference in order to present and discuss the most recent scientific and clinical achievements in oncology, both globally and in the Asia-Pacific region.

Gynecological cancers are among the most frequent cancers in women, making them a major public health concern. Because of a lack of cancer awareness, varied pathology, and a lack of effective screening facilities in Asian countries, most women report cancer at advanced stages, negatively impacting prognosis and clinical outcomes.

Gynecological Cancer Highlights

• Abstract Number – 288MO
• Abstract Type – Proffered Paper Session 
• Indication – Recurrent or Metastatic Cervical Cancer (R/MCC)

Title: InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, Phase III study of tisotumab vedotin vs. investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Executive Summary - Tisotumab vedotin demonstrated a significant and meaningful enhancement in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to chemotherapy in the Phase III InnovaTV 301 trial. The treatment maintained a manageable and acceptable toxicity profile for patients with recurrent or metastatic cervical cancer in the second or third line.

Main Content: TIVDAK (tisotumab vedotin) is an antibody-drug combination comprised of a tissue factor-directed human monoclonal antibody covalently coupled to the microtubule disruptor (monomethyl auristatin E) MMAE. 

Out of 660 individuals assessed for eligibility, 502 were randomly selected for the Phase III InnovaTV 301 trial (NCT04697628). TIVDAK exhibited a 30% decrease in the risk of death compared to the investigator's choice of chemotherapy. The outcomes revealed that, with a median follow-up of 10.8 months, the median OS was 11.5 months for TIVDAK, in contrast to 9.5 months for chemotherapy. The 12-month OS rates were 48.7% for TIVDAK and 35.3% for chemotherapy. The comprehensive findings of the research will be unveiled at the upcoming ESMO Asia.

 

List of Abstracts to be presented at ESMO Asia 2023